Indicators
Indicators
Value
Direction
MACD(12,26,9)
-3.439
Sell
RSI(14)
38.190
Neutral
STOCH(KDJ)(9,3,3)
58.136
Sell
ATR(14)
23.367
Low Volatility
CCI(14)
-17.976
Neutral
Williams %R
71.380
Sell
TRIX(12,20)
-0.660
Sell
StochRSI(14)
0.000
Sell
Search
Medpace Holdings Inc
MEDPAdd to Watchlist
417.290USD
-6.710-1.58%
Close 05/11, 16:00（ET）Quotes delayed by 15 min
11.92BMarket Cap
25.72P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Medpace Holdings Inc
Currency: USD Updated: 2026-05-08Key Insights
Medpace Holdings Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 44 out of 384 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 440.65.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Medpace Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Medpace Holdings Inc Highlights
StrengthsRisks
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 34.17% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.53B.
Undervalued
The company’s latest PE is 26.14, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 24.60M shares, decreasing 9.58% quarter-over-quarter.
Held by Joel Greenblatt
Star Investor Joel Greenblatt holds 17.24K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.05.
Analyst Rating
Based on
14
analysts
Hold
Current Rating
440.649
Target Price
+3.93%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-08The current financial score of Medpace Holdings Inc is 8.94, ranking 19 out of 384 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 706.60M, representing a year-over-year increase of 26.50%, while its net profit experienced a year-over-year increase of 8.09%.
Score
Financials
7.96
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.95
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.81
Medpace Holdings Inc's Company Valuation
Currency: USD Updated: 2026-05-08The current valuation score of Medpace Holdings Inc is 5.84, ranking 351 out of 384 in the Biotechnology & Medical Research industry. Its current P/E ratio is 26.14, which is 71.90% below the recent high of 44.93 and 21.47% above the recent low of 20.52.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 44/384
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-08The current earnings forecast score of Medpace Holdings Inc is 6.71, ranking 327 out of 384 in the Biotechnology & Medical Research industry. The average price target is 567.50, with a high of 655.00 and a low of 302.21.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
14
analysts
Hold
Current Rating
440.649
Target Price
+3.93%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Medpace Holdings Inc
MEDP
14
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
25
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-08The current price momentum score of Medpace Holdings Inc is 7.25, ranking 119 out of 384 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 512.31 and the support level at 354.34, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
425.422
Sell
MA10
420.357
Sell
MA20
452.774
Sell
MA50
464.610
Sell
MA100
505.236
Sell
MA200
513.643
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-08The current institutional shareholding score of Medpace Holdings Inc is 7.00, ranking 79 out of 384 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 86.14%, representing a quarter-over-quarter decrease of 0.93%. The largest institutional shareholder is The Vanguard, holding a total of 2.23M shares, representing 7.80% of shares outstanding, with 11.32% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Medpace Investors, L.L.C.
BlackRock Institutional Trust Company, N.A.
AQR Capital Management, LLC
Geode Capital Management, L.L.C.
State Street Investment Management (US)
Troendle (August J)
D. E. Shaw & Co., L.P.
1
2
Risk Assessment
Currency: USD Updated: 2026-05-08The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Medpace Holdings Inc is 7.52, ranking 11 out of 384 in the Biotechnology & Medical Research industry. The company's beta value is 1.19. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.19
VaR
+3.63%
240-Day Maximum Drawdown
+36.61%
240-Day Volatility
+63.71%
Return
Best Daily Return
60 days
+4.35%
120 days
+4.51%
5 years
+54.67%
Worst Daily Return
60 days
-22.63%
120 days
-22.63%
5 years
-22.63%
Sharpe Ratio
60 days
-0.04
120 days
-1.12
5 years
+0.61
Risk Assessment
Maximum Drawdown
240 days
+36.61%
3 years
+39.38%
5 years
+42.87%
Return-to-Drawdown Ratio
240 days
+1.20
3 years
+0.75
5 years
+0.67
Skewness
240 days
+6.89
3 years
+5.53
5 years
+4.49
Volatility
Realised Volatility
240 days
+63.71%
5 years
+49.35%
Standardised True Range
240 days
+4.05%
5 years
+2.49%
Downside Risk-Adjusted Return
120 days
-99.30%
240 days
-99.30%
Maximum Daily Upside Volatility
60 days
+50.75%
Maximum Daily Downside Volatility
60 days
+58.47%
Liquidity
Average Turnover Rate
60 days
+1.45%
120 days
+1.22%
5 years
--
Turnover Deviation
20 days
+38.52%
60 days
+15.76%
120 days
-3.28%
Peer Comparison
Biotechnology & Medical Research
Medpace Holdings Inc
MEDP
7.36 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.76 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AnaptysBio Inc
ANAB
8.43 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
